Drugs / IMGN151
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05527184 | Jan 2023 → Feb 2027 expected | cervical cancer, endometrial cancer, fallopian tube cancer, ovarian serous adenocarcinoma +1 | AbbVie | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07024784 | Jul 2025 → Jan 2028 expected | fallopian tube cancer, primary peritoneal carcinoma | AbbVie | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | AbbVie | Results ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting abbvie.com ↗
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced preclinical data for its next generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression. |
| 2020-05-15 | AbbVie | Results ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting abbvie.com ↗
In preclinical models, IMGN151 showed activity not only in high FRα-expressing tumors, but also improved activity in medium and low FRα-expressing tumors, suggesting promising potential in a broad set of patients with an array of tumor types. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | AbbVie | ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting abbvie.com ↗ |
| 2020-05-15 | AbbVie | ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting abbvie.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMGN151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024784 ↗ |
| Modality | Other / unclassified | “IMGN151 is an antibody-drug conjugate (ADC).” NCT05527184 ↗ |
| Route | Intravenous | “IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 every 3-week cycle (Q3W).” NCT05527184 ↗ |